Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients.

Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. Abstract Text:

Marcello Tonelli,Natasha Wiebe,Bruce Culleton,Helen Lee,Scott Klarenbach,Fiona Shrive,Braden Manns, ,Marcello Tonelli,Natasha Wiebe,Bruce Culleton,Helen Lee,Scott Klarenbach,Fiona Shrive,Braden Manns, ,

BACKGROUND: The relative effectiveness and safety of sevelamer for treatment of hyperphosphataemia in dialysis patients is uncertain, as compared with calcium-based phosphate binders. METHODS: We conducted a comprehensive search to identify all randomized cross-over or parallel group studies comparing sevelamer to any other therapy or placebo in adult dialysis patients. Study quality was assessed using the Chalmers Index. Data was extracted and checked using a standardized form and combined using a random effects model. RESULTS: We identified 14 primary publications of randomized trials (3193 participants) that were eligible for efficacy analysis. In analyses pooling, the 10 studies reporting on serum phosphate and calcium (2501 participants), serum phosphate was significantly lower with calcium-based phosphate binders by 0.12 mmol/l [95% confidence interval (CI) 0.05-0.19], compared with sevelamer. On-treatment calcium-phosphate product was not significantly lower in patients receiving calcium-based phosphate binders (0.12 mmol(2)/l(2), -0.05 to 0.29), compared with sevelamer. Overall mean difference in serum calcium was significantly lower with sevelamer therapy by 0.10 mmol/l (-0.12 to -0.07) and pooled on-treatment decrease in serum bicarbonate was significantly greater with sevelamer therapy by 2.8 mmol/l (2.2 to -3.5). In the five trials which reported all-cause mortality (2429 participants), the overall risk difference for all cause mortality in these five trials was similar between therapies (-2%, 95% CI -6-2). In the three trials which reported serious adverse events (2185 participants), there was a trend towards a lower risk in patients receiving calcium-based phosphate binders (13% lower, 95% CI -2-29). CONCLUSIONS: Compared with calcium-based phosphate binders, use of sevelamer in dialysis patients is associated with similar to slightly higher phosphate levels, similar calcium phosphate product, and slightly lower serum calcium levels. There was no evidence that sevelamer reduced all-cause mortality, cardiovascular mortality, the frequency of symptomatic bone disease or health-related quality of life.

Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. Publishing Authors By Initials

M Tonelli,N Wiebe,B Culleton,H Lee,S Klarenbach,F Shrive,B Manns, ,M Tonelli,N Wiebe,B Culleton,H Lee,S Klarenbach,F Shrive,B Manns, ,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Nephrology, dialysis, transplantation : official p

VOLUME: 22

Page Numbers: 2856-66

Journal Abbreviation: Nephrol. Dial. Transplant.

ISSN: 0931-0509

DAY: 1

MONTH: Oct

YEAR: 2007

Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8706402

Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients.

AFFILIATION: Foothills Medical Centre, 1403 29th Street NW, Calgary, Alberta T2N 2T9, Canada.

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Nephrol Dial Transplant

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients Related Publications

• A morphological study of the nucleus subpretectalis of the pigeon.
• A sonographically guided technique for central venous access.
• Activated protein C: cost-effective or costly?
• Comorbidities do not influence primary fistula success in incident hemodialysis patients: a prospective study.
• Evidence for posterior zonular fiber attachment on the anterior hyaloid membrane.
• Hepatitis D virus infection--not a vanishing disease in Europe!
• Mortality of Canadians treated by peritoneal dialysis in remote locations.
• Moving beyond the cost per quality-adjusted life year: modelling the budgetary impact and clinical outcomes associated with the use of sirolimus-eluting stents.
• New Monoterpenes from Cunila spicata.
• Optimizing the use of prescription drugs in Canada through the Common Drug Review.
• Prophylaxis, diagnosis and therapy of hepatitis B virus (HBV) infection: the german guidelines for the management of HBV infection1.
• Random field models in the textural analysis of ultrasonic images of the liver.
• Role of regulatory T cells for the treatment of type 1 diabetes mellitus.
• Simultaneous fundus imaging and optical coherence tomography of the mouse retina.
• Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients.
• The economics of home nocturnal hemodialysis: how should we cost the benefits?
• The effect of increasing dialysis dose in overweight hemodialysis patients on quality of life: a 6-week randomized crossover trial.
• The use of prostaglandins for regulation of the estrous cycle and as an abortifacient in cattle.
• [Acute liver failure: definition, etiology, clinical picture and prognosis]
• [Determination of the content of diphenylhydantoin in tablets.]
• [Early stages of rheumatic diseases.]
• [Hereditary hemorrhagic telangiectasia with hepatic involvement and including gastric vessels. A case report]
• [Immunology of primary biliary cirrhosis]
• [Indication for artificial nutrition: enteral and parenteral nutrition]
• [Isolation of Quinghaosen from Artemisia annua of European Sources.]
• [On problems of current interest in neuropsychiatric central hospitals]
• [Organ transplantation--gene therapy: interactions and transitions]
• [Reparative abilities following infectious and toxic damage of the liver]
• [Research forum II: Molecular biology research developments in gastroenterology. Introduction]
• [Therapy of viral hepatitis]